Gabriella Miller Kids First Research Act 2.0
Do you support it?
Want to know if it passes?
We'll email you when HR 6556 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 6556.
You're tracking HR 6556
We'll email you the moment it moves.
HR 6556 — Gabriella Miller Kids First Research Act 2.0
Last action — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Directs certain penalties assessed by the Securities Exchange Commission against pharmaceutical companies for specified violations to the 10-Year Pediatric Research Initiative Fund, an existing fund that supports pediatric disease research. In making allocations from that fund, the National Institutes of Health shall prioritize pediatric research that does not duplicate existing research activities.
Bill Text
We don't have the full text on file for this bill yet.
Read HR 6556 on the official United States source →Action History
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Sponsor introductory remarks on measure. (CR E373)
-
Introduced in House
Sponsors
- Jennifer Wexton · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 6556 do?
- Directs certain penalties assessed by the Securities Exchange Commission against pharmaceutical companies for specified violations to the 10-Year Pediatric Research Initiative Fund, an existing fund that supports pediatric disease research. In making allocations from that fund, the National Institutes of Health shall prioritize pediatric research that does not duplicate existing research activities.
- Who sponsors HR 6556?
- HR 6556 is sponsored by Jennifer Wexton (D).
- What is the current status of HR 6556?
- This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 6556?
- Track HR 6556 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 6556
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 6556
Last checked for changes about 15 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →